Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma

Autor: Dimopoulos, Meletios ^*, Bringhen, Sara, Anttila, Pekka, Capra, Marcelo, Cavo, Michele, Cole, Craig, Gasparetto, Cristina, Hungria, Vania, Jenner, Matthew, Vorobyev, Vladimir, Ruiz, Eduardo Yanez, Yin, Jian Y., Saleem, Rao, Hellet, Maeva, Macé, Sandrine, Paiva, Bruno, Vij, Ravi

Publikováno v: In Blood 4 March 2021 137(9):1154-1165

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma

Autor: Toni K. Choueiri, Thomas Powles, Laurence Albiges, Mauricio Burotto, Cezary Szczylik, Bogdan Zurawski, Eduardo Yanez Ruiz, Marco Maruzzo, Alberto Suarez Zaizar, Luis E. Fein, Fabio A. Schutz, Daniel Y.C. Heng, Fong Wang, Fabio Mataveli, Yu-Lin Chang, Maximiliano van Kooten Losio, Cristina Suarez, Robert J. Motzer

Publikováno v: New England Journal of Medicine. 388:1767-1778

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::80c5c5787987ecef603f402a5e5c6a63
https://doi.org/10.1056/nejmoa2212851

Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study

Autor: Junji Suzumiya, Seok-Goo Cho, Keum Young Ahn, Marek Trneny, Eduardo Yanez Ruiz, Christian Buske, Leslie Popplewell, Jose Mario Mariz, Michinori Ogura, Larry W. Kwak, Olga Samoilova, Tobias F. Menne, Hideyuki Nakazawa, Jin Seok Kim, Edvard Zhavrid, Gayane Tumyan, Nikolai Ilyin, Sunghyun Kim, Sang-Joon Lee, Wojciech Jurczak, Won Seog Kim, Juan-Manuel Sancho, A. Martínez

Publikováno v: Clinical Lymphoma Myeloma & Leukemia
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

INTRODUCTION: This double-blind, parallel-group, active-controlled phase III trial (NCT02260804) assessed CT-P10 and rituximab safety and efficacy in patients with previously untreated low-tumor-burden follicular lymphoma (LTBFL), including after a s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20ac8f612d136062b207eac5743a8146
https://doi.org/10.1016/j.clml.2021.08.005

Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial

Autor: Cornelius F. Waller, Maria Luisa T. Abesamis-Tiambeng, Charuwan Akewanlop, Eduardo Yanez Ruiz, Ihor Vynnychenko, Unmesh Gopalakrishnan, Abhijit Barve, Jay Herson, Ashwani Marwah, Virote Sriuranpong, Sirshendu Roy, Hope S. Rugo, Alexey Manikhas, Miguel Hernandez-Bronchud, Subramanian Loganathan, Hans Friedrich Koch, Joseph D. Parra, Sarika Deodhar, Igor Bondarenko, Eduardo J. Pennella

Publikováno v: Breast, Vol 58, Iss, Pp 18-26 (2021)
The Breast : Official Journal of the European Society of Mastology

Background Trastuzumab-dkst is a biosimilar of trastuzumab. The phase 3 HERITAGE trial demonstrated equivalent overall response rate (ORR) with trastuzumab-dkst or originator trastuzumab at 24 weeks in patients with HER2-positive metastatic breast ca

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28d8b0495b77dd28c7ee458c4ff26623
http://www.sciencedirect.com/science/article/pii/S0960977621003489